中国组织工程研究第20卷第36期2016–09–02出版ChineseJournalofTissueEngineeringResearchSeptember2,2016Vol.20,No.36ISSN2095-4344CN21-1581/RCODEN:ZLKHAH5385·研究原著·田雪品,女,1980年生,河北省承德市人,汉族,2015年河北医科大学毕业,硕士,主治医师,主要从事内分泌研究。中图分类号:R394.2文献标识码:B文章编号:2095-4344(2016)36-05385-07稿件接受:2016-07-12碱性成纤维细胞生长因子基因真核表达载体转染骨髓间充质干细胞移植治疗糖尿病田雪品,刘海英(承德市中心医院内分泌科,河北省承德市067000)引用本文:田雪品,刘海英.碱性成纤维细胞生长因子基因真核表达载体转染骨髓间充质干细胞移植治疗糖尿病[J].中国组织工程研究,2016,20(36):5385-5391.DOI:10.3969/j.issn.2095-4344.2016.36.010ORCID:0000-0002-5123-9594(田雪品)文章快速阅读:文题释义:转染:DNA小片段插入体细胞或细胞系的过程。若此DNA未与宿主细胞DNA整合而获表达,称“瞬时转染(transienttransfection)”;若与宿主细胞DNA整合并随后者的复制而复制称“稳定转染(stabletransfection)”。胰岛素抵抗:是指各种原因使胰岛素促进葡萄糖摄取和利用的效率下降,机体代偿性的分泌过多胰岛素产生高胰岛素血症,以维持血糖的稳定。胰岛素抵抗易导致代谢综合征和2型糖尿病。20世纪50年代Yallow等应用放射免疫分析技术测定血浆胰岛素浓度,发现血浆胰岛素水平较低的病人胰岛素敏感性较高,而血浆胰岛素较高的人对胰岛素不敏感,由此提出了胰岛素抵抗的概念。摘要背景:研究证实骨髓间充质干细胞可以明显提高糖尿病大鼠胰岛功能恢复及改善高血糖状态,可能与自体胰腺干细胞分化能力增强有关。目的:验证碱性成纤维细胞生长因子基因真核表达载体(PEGFP-C3-BFGF)转染骨髓间充质干细胞并移植入糖尿病大鼠体内后,对大鼠糖尿病的治疗效果。方法:通过重组腺病毒(Ad.aFGF)介导PEGFP-C3-BFGF转染入骨髓间充质干细胞,利用荧光显微镜观察PEGFP-C3-BFGF的表达。将80只SD大鼠随机分为正常对照组、糖尿病组、移植组及基因转染组,每组20只,采用链脲佐菌素(STZ)腹腔注射建立大鼠糖尿病模型,模型建立后于对照组给予门静脉注射生理盐水,糖尿病组门静脉注射PBS液,移植组门静脉注射骨髓间充质干细胞悬液1mL,基因转染组门静脉注射等量转染PEGFP-C3-BFGF的骨髓间充质干细胞悬液。利用RT-PCR法检测各组大鼠胰岛组织中基质金属蛋白酶的mRNA表达差异;检测移植后24h,3d,7d,14d,21d各组大鼠血糖水平;移植后3周利用ELISA法检测各组大鼠血浆胰岛素分泌水平;苏木精-伊红染色观察大鼠胰腺组织病理变化。结果与结论:①荧光显微镜观察到PEGFP-C3-BFGF转染入骨髓间充质干细胞48h后,呈现出明显的特异性绿色荧光;②移植后2周与对照组比较,糖尿病组的基质金属蛋白酶mRNA表达明显增加(P0.05),移植组及基因转染组基质金属蛋白酶mRNA的表达较糖尿病组明显下降(P0.05);③移植后不同时间点各组大鼠血糖比较,基因转染组移植组糖尿病组,但基因转染组仍对照组(均P0.05);④移植后不同时间点各组大鼠血浆胰岛素分泌水平比较,基因转染组移植组糖尿病组,但基因转染碱性成纤维细胞生长因子基因真核表达载体转染骨髓间充质干细胞移植治疗糖尿病大鼠正常对照组糖尿病组静脉注射PBS基因转染组静脉注射等量转染PEGFP-C3-BFGF的骨髓间充质干细胞悬液移植组静脉注射骨髓间充质干细胞悬液检测指标:(1)大鼠胰岛组织中基质金属蛋白酶的mRNA表达;(2)移植后24h,3d,7d,14d,21d大鼠血糖水平;(3)大鼠血浆胰岛素分泌水平;(4)大鼠胰腺组织病理变化建立大鼠糖尿病模型田雪品,等.碱性成纤维细胞生长因子基因真核表达载体转染骨髓间充质干细胞移植治疗糖尿病P.O.Box10002,Shenyang110180组仍对照组(均P0.05);⑤各组大鼠胰腺组织病理情况比较,移植组优于糖尿病组,基因转染组又优于移植组,接近于对照组。⑥结果说明,PEGFP-C3-BFGF转染骨髓间充质干细胞移植入糖尿病大鼠体内,可以改善大鼠血糖水平,促进胰岛素的分泌,其可能是通过下调基质金属蛋白酶mRNA的表达从而改善大鼠糖尿病病变程度。关键词:干细胞;移植;糖尿病;PEGFP-C3-BFGF;转染;骨髓间充质干细胞;大鼠;疗效主题词:干细胞;间质干细胞;移植;糖尿病;成纤维细胞生长因子2;组织工程EffectofbasicfibroblastgrowthfactorgenetransfectiononbonemarrowmesenchymalstemcelltransplantationfordiabetesmellitusTianXue-pin,LiuHai-ying(DepartmentofEndocrinology,ChengdeCentralHospital,Chengde067000,HebeiProvince,China)AbstractBACKGROUND:Existingstudieshaveshownthatbonemarrowmesenchymalstemcellscansignificantlyimproveisletfunctionindiabeticratstodecreaseexcessivelyhighbloodglucoselevel,whichmayberelatedtotheenhancementofdifferentiationabilityofautologoupancreaticstemcells.OBJECTIVE:Toobservethetherapeuticefficacyofbasicfibroblastgrowthfactorgeneeukaryoticexpressionvector(PEGFP-C3-BFGF)transfectionofbonemarrowmesenchymalstemcellsindiabeticrats.METHODS:Recombinantadenovirus(Ad.aFGF)mediatedPEGFP-C3-BFGFwastransfectedintobonemarrowmesenchymalstemcells,andPEGFP-C3-BFGFexpressionwasobservedusingfluorescencemicroscopy.EightySprague-Dawleyratswererandomlydividedintonormalcontrolgroup,diabetesgroup,transplantationgroup,genetransfectiongroup,with20ratsineachgroup.Aftermodeling,ratsindifferentgroupsweregivenportalveininjectionofnormalsaline,PBS,1mLofbonemarrowmesenchymalstemcellsuspension,and1mLofPEGFP-C3-BFGF-transfectedbonemarrowmesenchymalstemcellsuspension.RT-PCRmethodwasusedtodetectmRNAexpressionofmatrixmetalloproteinasesinpancreatictissueofratsineachgroup.Bloodglucoselevelsofratsweredetectedat24hours,3,7,14,21daysaftertransplantation.ELISAmethodwasusedtodetectplasmainsulinlevelsinrats.Pathologicalchangesofthepancreaswereobservedusinghematoxylin-eosinstaining.RESULTSANDCONCLUSION:Underthefluorescencemicroscope,PEGFP-C3-BFGFtransfectedintocellsafter48hoursshowedsignificantspecificredfluorescence.Twoweeksaftertransplantation,matrixmetalloproteinasesmRNAexpressionwassignificantlyincreasedinthediabetesgroupcomparedwiththecontrolgroup(P0.05),whileitwasdecreasedinthetransplantationandgenetransfectiongroupscomparedwiththediabetesgroup(P0.05).Aftertransplantation,thebloodglucoselevelsinratswererankedasfollows:controlgroupgenetransfectiongrouptransplantationgroupdiabetesgroup(P0.05),andtheplasmainsulinlevelsinratsrankedasfollows:controlgroupgenetransfectiongrouptransplantationgroupdiabetesgroup(P0.05).Pathologicalfindingsofthepancreasshowedthatthetransplantationgroupwassuperiortothediabetesgroup,butinferiortothegenetransfectiongroupthatwassimilartothecontrolgroup.AllthesefindingsindicatethatPEGFP-C3-BFGF-transfectedbonemarrowmesenchymalstemcelltransplantationcanimprovebloodglucoselevelsandstimulateinsulinsecretionindiabeticrats,whichmayimprovetheseverityofdiabetesmellitusbydecreasingthemRNAexpressionofmatrixmetalloproteinases.Subjectheadings:StemCells;MesenchymalStemCells;Transplantation;DiabetesMellitus;FibroblastGrowthFactor2;TissueEngineeringCitethisarticle:TianXP,LiuHY.Effectofbasicfibroblastgrowthfactorgenetransfectiononbonemarrowmesenchymalstemc